Inflammation as a validated prognostic determinant in carcinoma of unknown primary site

British Journal of Cancer

Volumn 110, Issue 1, 2014, Pages 208-213

  Mohamed, Z ^a   Pinato, D J ^b   Mauri, F A ^b   Chen, K W ^c   Chang, P M H ^c   Sharma, R ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

carcinoma of unknown primary; inflammation; prognosis; survival

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODIFIED GLASGOW PROGNOSTIC SCORE; ONCOLOGY; PATIENT REFERRAL; PRIORITY JOURNAL; SURVIVAL; VALIDATION PROCESS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84891867474     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.683     Document Type: Article

References (33)

1. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634-1639. (Pubitemid 34081505)
2. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89: 1022-1027. (Pubitemid 37239205)
3. Chen KW, Liu CJ, Lu HJ, Tzeng CH, Liu JH, Chiou TJ, Yen CC, Wang WS, Chao TC, Teng HW, Chen MH, Liu CY, Chang PM, Yang MH (2012) Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study. BMC Res Notes 5: 70.
4. Chua W, Clarke SJ, Charles KA (2012) Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer 20: 1869-1874.
5. Crumley AB, Stuart RC, Mckernan M, Mcdonald AC, McMillan DC (2008) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol 23: e325-e329.
6. Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200: 465-470. (Pubitemid 36818246)
7. Esper DH, Harb WA (2005) The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract 20: 369-376. (Pubitemid 47050807)
8. Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83: 1345-1350. (Pubitemid 44713065)
9. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G (2011) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22 (Suppl 6): vi64-vi68.
10. Forrest LM, McMillan DC, Mcardle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90: 1704-1706. (Pubitemid 38725637)
11. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N (2009) Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 35: 570-573.
12. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 88(1): 218-230.
13. Harrell F (2010) RMS: REgression Medelling Strategies. R package version 3: 0-0.
14. Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, Yamamoto N, Ishikawa Y, Yokoyama M, Saotome T, Terui Y, Hatake K (2010) Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol 21: 1163-1167.
15. Mayordomo JI, Guerra JM, Guijarro C, Garcia-Prats MD, Gomez A, Lopez-Brea M, Gonzalez R, Hergueta P, Lopez-Pino MA, Martinez-Tello F et al. (1993) Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori 79: 321-324. (Pubitemid 24098931)
16. McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67: 257-262.
17. McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39: 534-540.
18. Milovic M, Popov I, Jelic S (2002) Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit 8: MT25-MT30. (Pubitemid 34218474)
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET, Carbone (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
20. Pavlidis N (2012) Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets. Ann Oncol 23(Suppl 10): x282-x285.
21. Pavlidis N, Fizazi K (2009) Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 69: 271-278.
22. Pavlidis N, Petrakis D, Golfinopoulos V, Pentheroudakis G (2012) Long-term survivors among patients with cancer of unknown primary. Crit Rev Oncol Hematol 84: 85-92.
23. Penel N, Negrier S, Ray-Coquard I, Ferte C, Devos P, Hollebecque A, Sawyer MB, Adenis A, Seve P (2009) Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One 4: e6483.
24. Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N (2013) Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev 39: 701-708.
25. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47: 2633-2641.
26. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109: 205-212. (Pubitemid 46106235)
27. Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, Negrier S, Dumontet C, Mackey JR (2006a) Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 107: 2698-2705. (Pubitemid 44845626)
28. Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR (2006b) The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 106: 2058-2066. (Pubitemid 43673223)
29. Sharma R, Hook J, Kumar M, Gabra H (2008) Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 44: 251-256.
30. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197: 466-472.
31. Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M (2003) Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 163: 2221-2232. (Pubitemid 37466467)
32. Trivanovic D, Petkovic M, Stimac D (2009) New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis. Clin Oncol (R Coll Radiol) 21: 43-48.
33. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181-184. (Pubitemid 41254421)